Persistent Pulmonary Hypertension of the Newborn
16
1
2
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
18.8%
3 terminated out of 16 trials
70.0%
-16.5% vs benchmark
6%
1 trials in Phase 3/4
71%
5 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (16)
Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension
PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn
Milrinone in Congenital Diaphragmatic Hernia
The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns
Close Loop Smart Weaning for INO With PPHN
Persistent Pulmonary Hypertension of the Newborn
Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
NEURodevelopmental Outcome After Persistent Pulmonary Hypertension Of the Newborn
IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn
Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN)
Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn
Population Pharmacokinetics and Dosage Individualization of Oral Pulmonary Vasodilators in PPHN
Markers of Inflammation and Lung Recovery in ECMO Patients for PPHN
Pharmacokinetics of Sildenafil in Premature Infants
Plethismographic Perfusion Index in Neonates